These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 17109887)

  • 21. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
    Yu Y; Zhou Q; Hang Y; Bu X; Jia W
    Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
    Mondesire WH; Jian W; Zhang H; Ensor J; Hung MC; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2004 Oct; 10(20):7031-42. PubMed ID: 15501983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells.
    Paglin S; Lee NY; Nakar C; Fitzgerald M; Plotkin J; Deuel B; Hackett N; McMahill M; Sphicas E; Lampen N; Yahalom J
    Cancer Res; 2005 Dec; 65(23):11061-70. PubMed ID: 16322256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
    Vanderweele DJ; Rudin CM
    Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
    Nozawa H; Watanabe T; Nagawa H
    Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
    Dowsett M; Harper-Wynne C; Boeddinghaus I; Salter J; Hills M; Dixon M; Ebbs S; Gui G; Sacks N; Smith I
    Cancer Res; 2001 Dec; 61(23):8452-8. PubMed ID: 11731427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
    Liu ZJ; Zhu BT
    J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR; Murphy LC; Hall RE; Sutherland RL
    Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
    Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
    Gao HD; Sun JZ; Bi DS; Ma R
    Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
    Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.